Exploratory Study of Drug Sensitivity Prediction Software (IRCR-DReSS) With Patient-derived Tumor Cells of Metastatic Gastric Cancer

Phase 2

Completed

• Conditions: Stomach Neoplasms
• Interventions: Drug: Sunitinib; Drug: Imatinib; Drug: Gefitinib

• Registration Number: NCT03170180
• Lead Sponsor: Samsung Medical Center

Brief Summary

1. Metastatic gastric cancer patients who failed standard treatment will be enrolled in this study.

2. After consent form, patient-derived cancer cell will be collected and tested with 3 kinds of drugs (sunitinib, gefitinib, imatinib).

3. Drug sensitivity prediction software (IRCR-DReSS) will present level of sensitivity and patients will be treated with sensitive drugs.

4. Patients will be evaluated every 6 weeks.

Detailed Description

Not available

Study Timeline

• Study Start: 2017-03-01
• Study First Submitted: 2017-05-26
• Study First Submitted QC: 2017-05-26
• Study First Posted: 2017-05-30
• Primary Completion: 2021-10-31
• Study Completion: 2021-12-28
• Status Verified: 2022-06
• Last Update Submitted: 2022-06-13
• Last Update Posted: 2022-06-15

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 66

Inclusion Criteria

• age>-20
• metastatic gastric cancer
• life expectancy >-3 months
• ascites and pleural effusion that can be drained
• ECOG 0-2
• Proper organ function
• Patients who will be enrolled in sunitinib, gefitinib, imatinib clinical trial

Exclusion Criteria

• HBeAg, HCV, HIV (+)
• Active infection
• Uncontrolled systemic disease

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
sunitinib	Sunitinib	-
imatinib	Imatinib	-
gefitinib	Gefitinib	-

Primary Outcome Measures

Name	Time	Method
response rate	2 years

Trial Locations

Locations (1)

Samsung Medical Center; 🇰🇷 Seoul, Korea, Republic of